Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1184 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Lumasiran for primary hyperoxaluria type I	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
Lumasiran for primary hyperoxaluria type 1 in paediatric patients aged up to 5 years	Lumasiran (ALN-GO1)	Primary hyperoxaluria	Nephrology	2019	View \| Download
Lumacaftor and Ivacaftor (Orkambi) for Cystic Fibrosis Homozygous for the F508del Mutation in Patients Aged 6‐11 Years	Orkambi (fixed dose combination: Lumacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2018	View \| Download
Lumacaftor and Ivacaftor (Orkambi) for Cystic Fibrosis Homozygous for the F508del CFTR mutation in patients aged 2-5 years old	Orkambi (fixed dose combination: Lumacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2018	View \| Download
Lumacafor/ivacaftor (fixed-dose combination) for cystic fibrosis homozygous for F508del mutation in patients aged 12 to 23 months	Orkambi (fixed dose combination: Lumacaftor; Ivacaftor)	Cystic fibrosis	Genetic Disorders , Respiratory System	2019	View \| Download
Lorlatinib for advanced ALK-positive non-small cell lung cancer – first line	Lorlatinib (PF-06463922; Lorviqua)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2020	View \| Download
Lorlatinib (PF-06463922) for advanced ALK or ROS1 positive non-small cell lung cancer – second line	Lorlatinib (PF-06463922; Lorviqua)	Non-small-cell lung cancer (NSCLC)	Lung and Respiratory Cancer	2017	View \| Download
Loncastuximab Tesirine for relapsed or refractory diffuse large B-cell lymphoma – third line	Loncastuximab Tesirine (ADCT-402; Lonca; Zylonta)	Diffuse large B-cell lymphoma (DLBCL)	Haematological Cancer and Lymphomas	2021	View \| Download
Lonafarnib for Hutchinson-Gilford Progeria syndrome and progeroid laminopathies	Lonafarnib (Sarasar; EBP994; SCH 66336; Zokinvy)	Progeria	Genetic Disorders	2020	View \| Download
LN-145 for recurrent, metastatic or persistent cervical carcinoma	LN-145	Cervical cancer	Female Reproductive Cancer	2020	View \| Download